Skip to main content
SpringerLink
Log in

Erstes NOAK-Antidot in Kürze marktreif

  • AKTUELLE MEDIZIN_KRITISCH GELESEN
  • Published:
MMW - Fortschritte der Medizin Aims and scope

Idarucizumab, ein monoklonales Antikörper-Fragment, bindet an Dabigatran mit einer 350-fach höheren Affinität als an Thrombin und beendet die antikoagulative Wirkung innerhalb von Minuten.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Pollack C V, Reilly P A, Eikelboom J et al. Idarucizumab for Dabigatran Reversal. New Engl J Med. 2015;373:511–20

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    H. Holzgreve

Authors
  1. H. Holzgreve
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Holzgreve, H. Erstes NOAK-Antidot in Kürze marktreif. MMW - Fortschritte der Medizin 157, 34 (2015). https://doi.org/10.1007/s15006-015-3409-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-015-3409-3

Search

Navigation